Literature DB >> 6379044

Epidemiological and bacteriological investigation of Serratia marcescens epidemic in a nursery and in a neonatal intensive care unit.

D Montanaro, G M Grasso, I Annino, N De Ruggiero, A Scarcella, F Schioppa.   

Abstract

An epidemic caused by Serratia marcescens that involved 26 infants admitted to the Neonatal Intensive Care Unit (NICU) and 82 infants admitted to the Nursery of the 2nd Medical School of Naples is reported. Two different biotypes of S. marcescens with two completely different epidemiological patterns were identified. The prevalent biotype (A8b trigonelline-) was isolated in the delivery room, in the operating room, in the Nursery and in the NICU from items, healthy infant excreters and affected infants; the second biotype (A3a) was isolated only in the NICU from staff, two healthy infant excreters and two affected infants. Colonization of the throat and the gastrointestinal tract was frequent. Infected and colonized infants were the most important reservoir for serratia in the Nursery and in the NICU particularly for the type strain A3a. A mucus aspiration apparatus contaminated in the delivery room and the contamination of several instruments and items probably had a major role in the initiation and maintenance of the spread of the A8b strain. Mass contamination of the nursery has been related to overcrowding and a lack of the control measures; the transfer of high-risk colonized infants caused spread in the NICU. In the NICU the attack rate 26%; 69% of infants became ill; the case fatality ratio was 19%. Epidemiological investigation of the infants at risk showed some factors predisposing to infection with serratia. The hygienic measures failed to control the spread of serratia and it was necessary to refuse new admissions to pregnant women in order to decontaminate and re-organize the wards.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6379044      PMCID: PMC2129282          DOI: 10.1017/s0022172400060940

Source DB:  PubMed          Journal:  J Hyg (Lond)        ISSN: 0022-1724


  22 in total

1.  Serratia marcescens infections from inhalation therapy medications: nosocomial outbreak.

Authors:  C V Sanders; J P Luby; W G Johanson; J A Barnett; J P Sanford
Journal:  Ann Intern Med       Date:  1970-07       Impact factor: 25.391

2.  An outbreak of Serratia marcescens, and its control.

Authors:  H A Cabrera
Journal:  Arch Intern Med       Date:  1969-06

3.  Nonpigmented Serratia marcescens.

Authors:  E Clayton; A Von Graevenitz
Journal:  JAMA       Date:  1966-09-26       Impact factor: 56.272

4.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

5.  An outbreak of nosocomial infection due to multiply resistant Serratia marcescens: evidence of interhospital spread.

Authors:  D R Schaberg; R H Alford; R Anderson; J J Farmer; M A Melly; W Schaffner
Journal:  J Infect Dis       Date:  1976-08       Impact factor: 5.226

6.  Serratia marcescens colonising the gut.

Authors:  S R Jones; M Amon; C Falvey; K Patrick
Journal:  Lancet       Date:  1978-05-20       Impact factor: 79.321

7.  A nursery outbreak caused by Serratia marcescens--scalp-vein needles as a portal of entry.

Authors:  W E Stamm; C A Kolff; E M Dones; R Javariz; R L Anderson; J J Farmer; H R de Quinones
Journal:  J Pediatr       Date:  1976-07       Impact factor: 4.406

8.  Biotyping of Serratia marcescens and its use in epidemiological studies.

Authors:  P A Grimont; F Grimont
Journal:  J Clin Microbiol       Date:  1978-07       Impact factor: 5.948

9.  Epidemiological differentiation of Serratia marcescens: typing by bacteriocin sensitivity.

Authors:  J J Farmer
Journal:  Appl Microbiol       Date:  1972-02

10.  Bacteriocin (Marcescin) typing of clinical isolates of Serratia marcescens.

Authors:  W H Traub; E A Raymond; T S Startsman
Journal:  Appl Microbiol       Date:  1971-05
View more
  7 in total

1.  Use of colistin and sorbitol for better isolation of Serratia marcescens in clinical samples.

Authors:  G M Grasso; M M D'Errico; F Schioppa; F Romano; D Montanaro
Journal:  Epidemiol Infect       Date:  1988-10       Impact factor: 2.451

Review 2.  Serratia infections: from military experiments to current practice.

Authors:  Steven D Mahlen
Journal:  Clin Microbiol Rev       Date:  2011-10       Impact factor: 26.132

3.  Use of pulsed-field gel electrophoresis typing to study an outbreak of infection due to Serratia marcescens in a neonatal intensive care unit.

Authors:  G Miranda; C Kelly; F Solorzano; B Leanos; R Coria; J E Patterson
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

4.  Analysis of epidemiologic markers of nosocomial Serratia marcescens isolates with special reference to the Grimont biotyping system.

Authors:  J Sifuentes-Osornio; G M Ruiz-Palacios; D H Gröschel
Journal:  J Clin Microbiol       Date:  1986-02       Impact factor: 5.948

5.  Dissemination of cephalosporin-resistant Serratia marcescens strains producing a plasmidic SHV type beta-lactamase in Greek hospitals.

Authors:  D Gianneli; E Tzelepi; L S Tzouvelekis; A F Mentis; C Nikolopoulou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-09       Impact factor: 3.267

6.  Increased resistance to amikacin in a neonatal unit following intensive amikacin usage.

Authors:  I R Friedland; E Funk; M Khoosal; K P Klugman
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

7.  First Italian outbreak of VIM-producing Serratia marcescens in an adult polyvalent intensive care unit, August-October 2018: A case report and literature review.

Authors:  Maria Rosaria Iovene; Vincenzo Pota; Massimiliano Galdiero; Giusy Corvino; Federica Maria Di Lella; Debora Stelitano; Maria Beatrice Passavanti; Maria Caterina Pace; Aniello Alfieri; Sveva Di Franco; Caterina Aurilio; Pasquale Sansone; Vettakkara Kandy Muhammed Niyas; Marco Fiore
Journal:  World J Clin Cases       Date:  2019-11-06       Impact factor: 1.337

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.